Prudential Financial Inc Affimed N.V. Transaction History

Prudential Financial Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $124,961 - $191,337	-33,865 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $431,560 - $568,180	-80,365 Reduced 70.35%	33,865 $187,000
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $244,424 - $331,341	44,120 Added 62.93%	114,230 $706,000
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $545,455 - $799,254	70,110 New	70,110 $596,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.